Updates are available Correction dated 2021-06-01
Click to view Correction: https://doi.org/10.1007/s12185-021-03170-2
-
Authors
Kawabata, Hiroshi https://orcid.org/0000-0002-1918-8635
Fujimoto, Shino
Sakai, Tomoyuki
Yanagisawa, Hiroto
Kitawaki, Toshio
Nara, Kenji
Hagihara, Masao
Yamamoto, Hiroshi
Tanimizu, Masakuni
Kato, Chikako
Origuchi, Tomoki
Sunami, Kazutaka
Sunami, Yoshitaka
Masunari, Taro
Nakamura, Nobuhiko
Kobayashi, Masanori
Yamagami, Keiko
Miura, Katsuhiro
Takai, Kazue
Aoki, Sadao
Tsukamoto, Norifumi
Masaki, Yasufumi
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare
Ministry of Education, Culture, Sports, Science and Technology (17591060 and 15K09510)
Kanazawa Medical University (S2004-16, S2007-5, K2011-7, H2011-11, AR2012-06)
- License Information
-
More Information
Article History
Received: 22 February 2021
Revised: 22 April 2021
Accepted: 22 April 2021
First Online: 30 April 2021
Change Date: 1 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12185-021-03170-2
Declarations
:
: Dr. KAWABATA reports personal fees from Kyowa Hakko Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., and Nippon Shinyaku Co., Ltd. outside the submitted work; Dr. K. SUNAMI reports grants from Ono Pharmaceutical Co. Ltd., MSD K. K., Celgene Corporation, AbbVie GK., Takeda Pharmaceutical Co., Ltd., Sanofi K.K., Bristol-Myers Squibb, Daiichi Sankyo Co. Ltd., Alexion Pharmaceuticals Inc., GlaxoSmithKline K. K., Novartis Pharma K.K., and Janssen Pharmaceutical K.K., and personal fees from Celgene Corporation, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb, and Takeda Pharmaceutical Co., Ltd. outside the submitted work; Dr. Tsukamoto reports personal fees from Kyowa Hakko Kirin Co., Ltd. outside the submitted work; Dr. AOKI reports personal fees from AbbVie GK. and Janssen Pharmaceutical K.K. outside the submitted work; Dr. Masaki reports grants from Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., and Pfizer Seiyaku K. K. outside the submitted work.
